Companies: Merck & Co., Inc.
Drugs: belzutifan, Welireg, pembrolizumab, Keytruda, berahyaluronidase
FDA approves belzutifan plus pembrolizumab for adjuvant RCC
200% citation coverage3 regulatory sources1 peer-reviewed sources
Intelligence Snapshot
Executive Summary
The FDA approved belzutifan plus pembrolizumab as adjuvant therapy for clear cell RCC at high risk of recurrence following nephrectomy, based on phase 3 LITESPARK-022 data.
Key Insights
-
Belzutifan's FDA label now encompasses adjuvant RCC, advanced RCC (post-checkpoint…
Belzutifan's FDA label now encompasses adjuvant RCC, advanced RCC (post-checkpoint inhibitor and VEGF-TKI), and VHL-associated tumors including RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumors.
-
Multiple recruiting trials are evaluating belzutifan in neoadjuvant, recurrent, and other…
Multiple recruiting trials are evaluating belzutifan in neoadjuvant, recurrent, and other renal cell carcinoma settings.
Market Impact
| Regulatory | high |
|---|---|
| Commercial | high |
| Competitive | medium |
| Investment | high |
The FDA approved belzutifan plus pembrolizumab as adjuvant therapy for clear cell renal cell carcinoma at high risk of recurrence after nephrectomy. The catalyst is based on phase 3 LITESPARK-022 data and adds another regulatory milestone for belzutifan in the renal oncology space.
Loading intelligence…
Loading intelligence…
Loading intelligence…
Loading intelligence…
Quick Answer
Key Questions
- What changed with the FDA approval?
- Who is directly affected by this approval?
- What should regulatory and BD teams watch for next?
- Is belzutifan approved for use in Europe or other regions?
Executive Scorecard
Heuristic scores · directional, not investment adviceRegulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for belzutifan.
Unlock full calendar →Merck & Co., Inc. pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Contents14 sections
FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant Renal Cell Carcinoma
FDA Approval Expands Belzutifan Into the Adjuvant RCC Setting
The FDA approved belzutifan in combination with pembrolizumab as adjuvant therapy for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy. This approval represents a new indication for belzutifan, extending its regulatory footprint beyond the advanced disease setting where it was previously authorized.
The approval is grounded in data from the phase 3 LITESPARK-022 trial, which evaluated the combination in the adjuvant RCC population.
IntelligenceRegulatory Impact
FDA decisions frame this story. Regulatory relevance is high for renal cell carcinoma, with belzutifan and Welireg most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.
What Indications Does Belzutifan Now Carry?
Belzutifan (Welireg) is a hypoxia-inducible factor inhibitor manufactured by Merck Sharp & Dohme LLC and administered orally. The drug's label now encompasses multiple indications tied to renal pathology.
On December 14, 2023, the FDA approved belzutifan for patients with advanced renal cell carcinoma following treatment with a PD-1/PD-L1 checkpoint inhibitor and a VEGF-TKI. Beyond RCC, belzutifan is also indicated for treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.
IntelligenceCompetitive Intelligence
Merck & Co., Inc. are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.
What Is the Evidence Base for the Approval?
The phase 3 LITESPARK-022 trial provided the pivotal data supporting the FDA's approval of adjuvant belzutifan and pembrolizumab. The trial evaluated the combination in patients with clear cell RCC at high risk of recurrence following nephrectomy. Specific efficacy and safety data from LITESPARK-022 have not been detailed in the regulatory materials reviewed here.
IntelligenceMarket Signals
Commercial pull is high and investment relevance high for renal cell carcinoma. Expect implications for pricing, access, and launch sequencing.
Recruiting Trials Evaluating Belzutifan in Renal Cell Carcinoma
Several recruiting trials are currently enrolling patients to study belzutifan in RCC settings. A phase 2 trial (NCT07187778) is evaluating single-agent belzutifan or pembrolizumab versus combination as neoadjuvant therapy in clear cell renal cell carcinoma, sponsored by M.D. Anderson Cancer Center.
A phase 3 trial (NCT07227402) is recruiting patients to evaluate belzutifan and zanzalintinib in people with recurrent kidney cancer following adjuvant therapy, sponsored by Merck Sharp & Dohme LLC.
An extension study (NCT07405164) is enrolling participants from other belzutifan trials, while a phase 3 trial (NCT07489495) is recruiting patients with renal cell carcinoma to evaluate belzutifan and zanzalintinib.
IntelligenceStrategic Takeaways
The FDA approved belzutifan plus pembrolizumab as adjuvant therapy for clear cell RCC at high risk of recurrence following nephrectomy, based on phase 3 LITESPARK-022 data. Belzutifan's FDA label now encompasses adjuvant RCC, advanced RCC (post-checkpoint inhibitor and VEGF-TKI), and VHL-associated tumors including RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumors. Multiple recruiting trials are evalua
Key Takeaways
- The FDA approved belzutifan plus pembrolizumab as adjuvant therapy for clear cell RCC at high risk of recurrence following nephrectomy, based on phase 3 LITESPARK-022 data.
- Belzutifan's FDA label now encompasses adjuvant RCC, advanced RCC (post-checkpoint inhibitor and VEGF-TKI), and VHL-associated tumors including RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumors.
- Multiple recruiting trials are evaluating belzutifan in neoadjuvant, recurrent, and other renal cell carcinoma settings.
IntelligenceEvidence Quality
Grounded in 3 regulatory sources and 1 peer-reviewed source.
Drug Snapshot
| Drug | belzutifan |
|---|---|
| Generic name | BELZUTIFAN |
| Drug class | Hypoxia-inducible Factor Inhibitor [EPC] |
| Manufacturer | Merck Sharp & Dohme LLC |
| Route | ORAL |
| Indication | 1 INDICATIONS AND USAGE WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) |
Regulatory Summary
- Approved indication: 1 INDICATIONS AND USAGE WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1)
- belzutifan is_class Hypoxia-inducible Factor Inhibitor [EPC]
- Merck Sharp & Dohme LLC develops belzutifan
Trial Snapshot
| Trial | Title | Status | Phase | Sponsor |
|---|---|---|---|---|
| NCT07187778 | Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) | RECRUITING | PHASE2 | M.D. Anderson Cancer Center |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) | RECRUITING | PHASE3 | Merck Sharp & Dohme LLC |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | RECRUITING | PHASE3 | Merck Sharp & Dohme LLC |
| NCT07489495 | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) | RECRUITING | PHASE3 | Merck Sharp & Dohme LLC |
| NCT07377526 | Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer | RECRUITING | PHASE1, PHASE2 | M.D. Anderson Cancer Center |
Competitor Matrix
| Company / Program | Indication | Active trials |
|---|---|---|
| National Cancer Institute (NCI) | renal cell carcinoma | 2 |
| M.D. Anderson Cancer Center | renal cell carcinoma | 2 |
| Merck Sharp & Dohme LLC | renal cell carcinoma | 2 |
| West Virginia University | renal cell carcinoma | 1 |
| OHSU Knight Cancer Institute | renal cell carcinoma | 1 |
Timeline
- Recruiting trial NCT07187778 (PHASE2)
- Recruiting trial NCT07227402 (PHASE3)
- Recruiting trial NCT07405164 (PHASE3)
- Recruiting trial NCT07489495 (PHASE3)
- Recruiting trial NCT07377526 (PHASE1, PHASE2)
Frequently Asked Questions
What changed with the FDA approval?
The FDA approved belzutifan in combination with pembrolizumab as adjuvant therapy for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy. This is a new indication for belzutifan.
Who is directly affected by this approval?
Merck Sharp & Dohme LLC manufactures belzutifan, and U.S. patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy are eligible for the newly approved treatment.
What should regulatory and BD teams watch for next?
Teams should monitor for updates to the FDA label and regulatory communications. Watch for trial readouts or enrollment updates from the neoadjuvant phase 2 trial (NCT07187778), the recurrent disease phase 3 trial (NCT07227402), and other recruiting belzutifan studies in RCC.
Is belzutifan approved for use in Europe or other regions?
The evidence provided covers FDA approval only. For regulatory status in Europe, the United Kingdom, or other jurisdictions, consult EMA or regional regulatory authority databases.
Related profiles
Related coverage
Continue Exploring
Jump into the entities behind this story.
Ask AI About renal cell carcinoma
Grounded in NovaPharmaNews intelligence. Pick a prompt to start.
Follow belzutifan developments
FDA renal cell carcinoma alerts and belzutifan pipeline updates, every Monday.
- Sources analyzed
- 1
- Evidence strength
- 100/100
- Last verified
- Jun 15, 2026
- AI-assisted review
- Yes
- Editorial review
- Dr. Sarah Chen
Critical source quality · grounded in cited primary and secondary sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
